4/25/2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment

Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders

Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation

4/12/2022

News

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

Archives

Categories

COMPANY / RESEARCH / INVESTORS / NEWS / CONTACT